As the US Food and Drug Administration grappled with conducting on-site facility inspections in calendar year 2021, agency data show that the number of quality-related warning letters sent to device makers ticked up 33% from the prior year.
The FDA told Medtech Insight it mailed 28 quality-related enforcement missives to device makers last year – seven more than it sent in 2020, when on-site in-person inspections all but...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?